Alexandria T Phan1, Daniel M Halperin1, Jennifer A Chan2, David R Fogelman1, Kenneth R Hess3, Paige Malinowski2, Eileen Regan2, Chaan S Ng4, James C Yao5, Matthew H Kulke2. 1. Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. 2. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. 3. Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA. 4. Department of Diagnostic Radiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. 5. Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: jyao@mdanderson.org.
Abstract
BACKGROUND: Treatment options for advanced, well-differentiated neuroendocrine tumours (NETs) remain scarce. Pazopanib is an orally bioavailable, small molecule, multitargeted kinase inhibitor that inhibits VEGF receptors 1, 2, and 3. We did a study of the efficacy of pazopanib with depot octreotide in patients with advanced NETs. METHODS: We did a parallel cohort study of patients with metastatic or locally advanced grade 1-2 carcinoid tumours or pancreatic NETs, by use of a single-group, two-stage design. Patients received pazopanib 800 mg orally once per day and octreotide at their preprotocol dosage. The primary endpoint was the proportion of patients achieving an objective response, as assessed by investigators, by intention-to-treat analysis. This study is registered with ClinicalTrials.gov, identifier NCT00454363, and was completed in March, 2014. FINDINGS: Between April 12, 2007, and July 2, 2009, we enrolled 52 patients, including 32 individuals with pancreatic NETs and 20 individuals with carcinoid tumours. Seven (21·9%, 95% CI 11·0-38·8) of 32 patients with pancreatic NETs achieved an objective response. We detected no responses in the first stage of the cohort with carcinoid tumours, and we terminated accrual at 20 patients. Toxic effects included one patient with grade 4 hypertriglyceridaemia and one with grade 4 thrombosis, with the most common grade three events being aminotransferase increases and neutropenia, each of which happened in 3 patients. In all 52 patients, the most frequently observed toxic effects were fatigue (39 [75%]), nausea (33 [63%]), diarrhoea (33 [63%]), and hypertension (28 [54%]). INTERPRETATION: Treatment with pazopanib is associated with tumour response for patients with pancreatic NETs, but not for carcinoid tumours; a randomised controlled phase 3 study to assess pazopanib in advanced pancreatic NETs is warranted. FUNDING: US National Cancer Institute of the National Institutes of Health.
BACKGROUND: Treatment options for advanced, well-differentiated neuroendocrine tumours (NETs) remain scarce. Pazopanib is an orally bioavailable, small molecule, multitargeted kinase inhibitor that inhibits VEGF receptors 1, 2, and 3. We did a study of the efficacy of pazopanib with depot octreotide in patients with advanced NETs. METHODS: We did a parallel cohort study of patients with metastatic or locally advanced grade 1-2 carcinoid tumours or pancreatic NETs, by use of a single-group, two-stage design. Patients received pazopanib 800 mg orally once per day and octreotide at their preprotocol dosage. The primary endpoint was the proportion of patients achieving an objective response, as assessed by investigators, by intention-to-treat analysis. This study is registered with ClinicalTrials.gov, identifier NCT00454363, and was completed in March, 2014. FINDINGS: Between April 12, 2007, and July 2, 2009, we enrolled 52 patients, including 32 individuals with pancreatic NETs and 20 individuals with carcinoid tumours. Seven (21·9%, 95% CI 11·0-38·8) of 32 patients with pancreatic NETs achieved an objective response. We detected no responses in the first stage of the cohort with carcinoid tumours, and we terminated accrual at 20 patients. Toxic effects included one patient with grade 4 hypertriglyceridaemia and one with grade 4 thrombosis, with the most common grade three events being aminotransferase increases and neutropenia, each of which happened in 3 patients. In all 52 patients, the most frequently observed toxic effects were fatigue (39 [75%]), nausea (33 [63%]), diarrhoea (33 [63%]), and hypertension (28 [54%]). INTERPRETATION: Treatment with pazopanib is associated with tumour response for patients with pancreatic NETs, but not for carcinoid tumours; a randomised controlled phase 3 study to assess pazopanib in advanced pancreatic NETs is warranted. FUNDING: US National Cancer Institute of the National Institutes of Health.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Bernard Escudier; Camillo Porta; Petri Bono; Thomas Powles; Tim Eisen; Cora N Sternberg; Jürgen E Gschwend; Ugo De Giorgi; Omi Parikh; Robert Hawkins; Emmanuel Sevin; Sylvie Négrier; Sadya Khan; Jose Diaz; Suman Redhu; Faisal Mehmud; David Cella Journal: J Clin Oncol Date: 2014-03-31 Impact factor: 44.544
Authors: Martyn E Caplin; Marianne Pavel; Jarosław B Ćwikła; Alexandria T Phan; Markus Raderer; Eva Sedláčková; Guillaume Cadiot; Edward M Wolin; Jaume Capdevila; Lucy Wall; Guido Rindi; Alison Langley; Séverine Martinez; Joëlle Blumberg; Philippe Ruszniewski Journal: N Engl J Med Date: 2014-07-17 Impact factor: 91.245
Authors: John D Hainsworth; Mark S Rubin; Edward R Arrowsmith; James Khatcheressian; Edward J Crane; Luis A Franco Journal: Clin Genitourin Cancer Date: 2013-05-09 Impact factor: 2.872
Authors: M Quintela-Fandino; M Krzyzanowska; G Duncan; A Young; M J Moore; E X Chen; A Stathis; R Colomer; J Petronis; M Grewal; S Webster; L Wang; L L Siu Journal: Br J Cancer Date: 2013-02-14 Impact factor: 7.640
Authors: Joshua M Francis; Adam Kiezun; Alex H Ramos; Stefano Serra; Chandra Sekhar Pedamallu; Zhi Rong Qian; Michaela S Banck; Rahul Kanwar; Amit A Kulkarni; Anna Karpathakis; Veronica Manzo; Tanupriya Contractor; Juliet Philips; Elizabeth Nickerson; Nam Pho; Susanne M Hooshmand; Lauren K Brais; Michael S Lawrence; Trevor Pugh; Aaron McKenna; Andrey Sivachenko; Kristian Cibulskis; Scott L Carter; Akinyemi I Ojesina; Samuel Freeman; Robert T Jones; Douglas Voet; Gordon Saksena; Daniel Auclair; Robert Onofrio; Erica Shefler; Carrie Sougnez; Jonna Grimsby; Lisa Green; Niall Lennon; Tim Meyer; Martyn Caplin; Daniel C Chung; Andreas S Beutler; Shuji Ogino; Christina Thirlwell; Ramesh Shivdasani; Sylvia L Asa; Chris R Harris; Gad Getz; Matthew Kulke; Matthew Meyerson Journal: Nat Genet Date: 2013-11-03 Impact factor: 38.330
Authors: H K Ahn; J Y Choi; K-M Kim; H Kim; S-H Choi; S H Park; J O Park; H Y Lim; W K Kang; J Lee; Y S Park Journal: Br J Cancer Date: 2013-08-29 Impact factor: 7.640